Literature DB >> 1718244

Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles.

S Kit1, M Kit, R D DiMarchi, S P Little, C Gale.   

Abstract

Modified-live, attenuated infectious bovine rhinotracheitis (IBR) hybrid virus vaccines have been constructed by inserting in the major IBRV glycoprotein gIII gene chemically synthesized deoxyribonucleotide sequences encoding the bovine growth hormone signal sequence and monomeric or dimeric forms of the foot and mouth disease virus (FMDV) VP 1 epitope sequences. The foreign DNA sequences were inserted at the N-terminal end of the IBRV gIII coding sequence and were driven by the IBRV gIII promoter. The sequences encoding the first 38 and the first 21 amino acids of the IBRV gIII were deleted from the hybrid viruses containing inserts of the monomeric and dimeric FMDV epitope sequences, respectively, to avoid redundant signal sequences. Plaque immunoassay experiments with guinea pig and bovine anti-FMDV peptide antisera, and with anti-IBRV gIII monoclonal antibodies demonstrated that IBRV-FMDV fusion proteins were expressed in virus-infected MDBK cells. Immunoelectron microscopy analyses demonstrated that the IBRV-FMDV fusion proteins were expressed as repeated structures on the surface of virus particles. Experiments showed that the recombinant IBRV-FMDV viruses protected cattle from IBRV (Cooper) challenge and induced anti-FMDV peptide antibodies, thereby demonstrating that the FMDV epitopes were expressed in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718244     DOI: 10.1007/bf01310945

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  24 in total

1.  Herpes simplex virus DNA isolation from infected cells with a novel procedure.

Authors:  P F Pignatti; E Cassai; G Meneguzzi; N Chenciner; G Milanesi
Journal:  Virology       Date:  1979-02       Impact factor: 3.616

2.  Recombinant herpesviral proteins produced by cell-free translation provide a novel approach for the mapping of T lymphocyte epitopes.

Authors:  T P Leary; G A Splitter
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

3.  Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.

Authors:  Q C Xie; D McCahon; J R Crowther; G J Belsham; K C McCullough
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

4.  Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus.

Authors:  T R Doel; C Gale; C M Do Amaral; G Mulcahy; R Dimarchi
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

5.  Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals.

Authors:  M P Broekhuijsen; J M van Rijn; A J Blom; P H Pouwels; B E Enger-Valk; F Brown; M J Francis
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

6.  A multisite-directed mutagenesis using T7 DNA polymerase: application for reconstructing a mammalian gene.

Authors:  T Z Su; M R el-Gewely
Journal:  Gene       Date:  1988-09-15       Impact factor: 3.688

7.  Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.

Authors:  N R Parry; P V Barnett; E J Ouldridge; D J Rowlands; F Brown
Journal:  J Gen Virol       Date:  1989-06       Impact factor: 3.891

8.  Mapping of 10 epitopes on bovine herpesvirus type 1 glycoproteins gI and gIII.

Authors:  D R Fitzpatrick; M J Redmond; S K Attah-Poku; S van Drunen Littel-van den Hurk; L A Babiuk; T J Zamb
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

9.  Nucleotide sequence of bovine herpesvirus type 1 glycoprotein gIII, a structural model for gIII as a new member of the immunoglobulin superfamily, and implications for the homologous glycoproteins of other herpesviruses.

Authors:  D R Fitzpatrick; L A Babiuk; T J Zamb
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

10.  Nucleotide sequence of the marmoset herpesvirus thymidine kinase gene and predicted amino acid sequence of thymidine kinase polypeptide.

Authors:  H Otsuka; S Kit
Journal:  Virology       Date:  1984-06       Impact factor: 3.616

View more
  7 in total

1.  Approaches for genetic purity testing of live recombinant viral vaccines using a human adenovirus:rabies model.

Authors:  C Lutze-Wallace; T Sapp; S A Nadin-Davis; A Wandeler
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

2.  In vitro assessments of the genetic stability of a live recombinant human adenovirus vaccine against rabies.

Authors:  C Lutze-Wallace; T Sapp; M Sidhu; A Wandeler
Journal:  Can J Vet Res       Date:  1995-04       Impact factor: 1.310

3.  The class II membrane glycoprotein G of bovine respiratory syncytial virus, expressed from a synthetic open reading frame, is incorporated into virions of recombinant bovine herpesvirus 1.

Authors:  G Kühnle; A Heinze; J Schmitt; K Giesow; G Taylor; I Morrison; F A Rijsewijk; J T van Oirschot; G M Keil
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Construction of bovine herpesvirus-1 (BHV-1) recombinants which express pseudorabies virus (PRV) glycoproteins gB, gC, gD, and gE.

Authors:  H Otsuka; X Xuan
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

5.  Expression of porcine pseudorabies virus genes by a bovine herpesvirus-1 (infectious bovine rhinotracheitis virus) vector.

Authors:  S Kit; H Otsuka; M Kit
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 6.  Viral vectors for veterinary vaccines.

Authors:  M Sheppard
Journal:  Adv Vet Med       Date:  1999

Review 7.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.